cloxacillin has been researched along with aztreonam in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Braveny, I; Machka, K; Milatovic, D | 1 |
| Elliott, CR; Pater, JL | 1 |
| Alsina, J; Castelao, AM; Cruzado, JM; Gilvernet, S; Grinyó, JM; Riera, L; Serón, D; Soto, K; Torras, J | 1 |
| Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Castanheira, M; Samuelsen, Ø; Spencer, J; Walsh, TR | 1 |
| Beceiro, A; Bou, G; Cisneros, JM; Fernández-Cuenca, F; Martínez-Martínez, L; Pachón, J; Pascual, A; Pérez, A; Rodríguez-Baño, J; Vila, J | 1 |
| Kotsakis, SD; Miriagou, V; Tzelepi, E; Tzouvelekis, LS; Whichard, JM; Zioga, A | 1 |
| Kotsakis, SD; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Ghori, S; Griggs, DJ; Johnson, MM; Mott, A; Peake, L; Piddock, LJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Hayashi-Nishino, M; Nishino, K; Yamaguchi, A; Yamasaki, S | 1 |
| Anderson, KC; Kellogg, GE; Sarkar, A | 1 |
| Bommareddy, A; Gionfriddo, MR; Heindel, GA; Mukhija, P; Vanwert, AL; Witkowski, S; Wolman, AT | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barbosa, G; Barreiro, EJ; Lima, LM; Silva, BNMD | 1 |
2 review(s) available for cloxacillin and aztreonam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
β-lactam antibiotics: An overview from a medicinal chemistry perspective.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Chemistry, Pharmaceutical; Humans; Hydrolysis; Models, Chemical; Molecular Structure | 2020 |
2 trial(s) available for cloxacillin and aztreonam
| Article | Year |
|---|---|
The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients.
Topics: Acute Disease; Agranulocytosis; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Cloxacillin; Drug Therapy, Combination; Fever; Humans; Infection Control; Leukemia; Lymphoma; Moxalactam; Multicenter Studies as Topic; Neoplasms; Neutropenia; Prognosis; Random Allocation; Tobramycin | 1988 |
Prophylaxis of urinary tract infection in renal transplantation: comparison of three different protocols using ceftriaxone-cloxacillin, aztreonam-cloxacillin, or aztreonam-amoxycillin-clavulanic acid.
Topics: Adult; Amoxicillin; Aztreonam; Ceftriaxone; Cloxacillin; Drug Therapy, Combination; Female; Follow-Up Studies; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Histocompatibility Testing; Humans; Kidney Transplantation; Male; Postoperative Complications; Urinary Tract Infections | 1995 |
11 other study(ies) available for cloxacillin and aztreonam
| Article | Year |
|---|---|
In vitro interactions of carumonam in combination with coumermycin, teicoplanin, flucloxacillin and vancomycin.
Topics: Aminocoumarins; Anti-Bacterial Agents; Aztreonam; Bacteria; Cloxacillin; Coumarins; Drug Therapy, Combination; Enterobacter; Floxacillin; Glycopeptides; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Serratia marcescens; Teicoplanin; Vancomycin | 1987 |
Plasmid-encoded ACC-4, an extended-spectrum cephalosporinase variant from Escherichia coli.
Topics: Anti-Bacterial Agents; Cephalosporinase; Culture Media; DNA Primers; Drug Resistance, Bacterial; Escherichia coli; Kinetics; Models, Molecular; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Spectrophotometry, Ultraviolet | 2007 |
Kinetic characterization of VIM-7, a divergent member of the VIM metallo-beta-lactamase family.
Topics: Acremonium; Bacterial Proteins; beta-Lactamases; Catalysis; Catalytic Domain; Cefepime; Ceftazidime; Cephalosporins; Kinetics; Models, Molecular; Mutation; Penicillinase; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Substrate Specificity | 2008 |
Genetic variability among ampC genes from acinetobacter genomic species 3.
Topics: Acinetobacter; Acinetobacter baumannii; Amino Acid Sequence; Ampicillin Resistance; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; Escherichia coli; Genes, Bacterial; Genetic Variation; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Spain | 2009 |
CMY-31 and CMY-36 cephalosporinases encoded by ColE1-like plasmids.
Topics: Alleles; Amino Acid Sequence; Amino Acid Substitution; Arginine; Base Sequence; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporinase; Citrobacter freundii; Cysteine; DNA Transposable Elements; DNA, Bacterial; Escherichia coli; Genes, Bacterial; Glutamine; Humans; Hydrolysis; Inhibitory Concentration 50; Isoelectric Point; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Models, Genetic; Models, Molecular; Molecular Sequence Data; Plasmids; Salmonella enterica; Sequence Analysis, DNA; Species Specificity; Substrate Specificity; Transformation, Genetic | 2009 |
Extended-spectrum properties of CMY-30, a Val211Gly mutant of CMY-2 cephalosporinase.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Cephalosporins; Escherichia coli Proteins; Protein Binding; Protein Structure, Secondary | 2009 |
Beta-lactamase-mediated beta-lactam resistance in Campylobacter species: prevalence of Cj0299 (bla OXA-61) and evidence for a novel beta-Lactamase in C. jejuni.
Topics: Amino Acid Sequence; Amoxicillin; Ampicillin; Animals; Anti-Bacterial Agents; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Blotting, Southern; Campylobacter jejuni; Carbenicillin; Cephalosporins; Chickens; Cloxacillin; Isoelectric Focusing; Mass Spectrometry; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillins; Piperacillin; Polymerase Chain Reaction; Sequence Alignment; Ticarcillin | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Copper; Drug Resistance, Bacterial; Drug Resistance, Multiple; Escherichia coli; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Lipoproteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Computational Biology; Drug Resistance, Bacterial; Hydrophobic and Hydrophilic Interactions; Ligands; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Regression Analysis; Thermodynamics | 2012 |
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Biological Transport; Cell Line, Transformed; Humans; Mice; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Solubility; Structure-Activity Relationship | 2013 |